FDA Approved: LITHIUM — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

The FDA approved a supplemental application for Lithium from PAI Holdings dba PAI Pharma, updating an already-approved product under the ANDA pathway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Lithium (Lithium carbonate)

Snippet

SUPPL AP for LITHIUM (LITHIUM)